Ma Iulai 31, ua hoʻolaha pū ʻo AstraZeneca lāua ʻo Merck & Co. ua ʻāpono ʻia kā lākou mea hoʻopaʻa PARP ʻo Lynparza, i hui pū ʻia me Abiraterone a me prednisolone, ma Kina no ka mālama ʻana i nā poʻe maʻi makua me ka maʻi kanesa prostate metastatic castration-resistant (mCRPC) nāna e lawe i nā mutations germline a i ʻole somatic BRCA (gBRCAm a i ʻole sBRCAm).
I kēia manawa, nui nā hoʻokolohua lapaʻau o nā ʻenehana anti-cancer hou ma Kina e ʻimi nei i nā maʻi. I ke kūkākūkā ʻana i nā lāʻau lapaʻau a me nā ʻenehana hou, hiki iā ʻoe ke hoʻokaʻaʻike aku i ka Beijing South Region Oncology Hospital International Department.
Helu Kelepona：4008803716
ʻIkepili WeChat: 17801183037
Leka uila:myimmnet@163.com
ʻO Lynparza (olaparib) kahi mea hoʻopaʻa PARP mua loa o ka papa a ʻo ia ka lāʻau lapaʻau mua i kuhikuhi ʻia e ālai i ka pane hōʻino DNA (DDR) i loko o nā cell/tumors e hūnā ana i kahi hemahema i ka HRR, e like me nā mutations ma BRCA1 a/a i ʻole BRCA2. ʻO ka pale ʻana o PARP me Lynparza e alakaʻi ai i ka pahele ʻana o PARP i hoʻopaʻa ʻia i nā haki kaula hoʻokahi DNA, ka hoʻopaneʻe ʻana o nā ʻōpuʻu replication, ko lākou hiolo ʻana a me ka hanauna ʻana o nā haki kaula pālua DNA a me ka make ʻana o nā cell cancer.
Ua hoʻokumu nui ʻia kēia ʻae ʻana ma nā hopena loiloi subgroup mai nā hui honua a me Kina o ka hoʻokolohua PROpel Phase III. He hoʻokolohua lapaʻau randomized, double-blind, multicenter Phase III ʻo PROpel e loiloi ana i ka pono, ka palekana, a me ka hiki ke hoʻomanawanui iā Lynparza i hui pū ʻia me Abiraterone a me prednisolone i hoʻohālikelike ʻia me ka placebo me Abiraterone a me prednisolone i nā maʻi kāne me mCRPC i loaʻa ʻole i ka chemotherapy mua a i ʻole ka lāʻau hormonal hou (NHA) ma ke kahua mCRPC.
Ua hōʻike ʻia nā ʻikepili mai ka hui honua o nā maʻi me nā hoʻololi BRCA ua hōʻike ʻo Lynparza i hui pū ʻia me Abiraterone i kahi hoʻomaikaʻi koʻikoʻi ma ke ʻano lapaʻau i ka radiographic progression-free survival (rPFS) i hoʻohālikelike ʻia me ka Abiraterone monotherapy. Ua hōʻike ka loiloi subgroup o nā maʻi me nā hoʻololi BRCA i ka hui honua ua hōʻemi ʻo Lynparza i hui pū ʻia me Abiraterone i ka pilikia o ka holomua ʻana o ka maʻi a i ʻole ka make ma 76% a me ka pilikia o ka make ma 70%. ʻAʻole i hiki i ka median rPFS a me ka median overall survival (OS) i ka hui Lynparza me Abiraterone, ʻoiai ʻo ka median rPFS a me ka median OS i ka hui monotherapy Abiraterone he 8 mahina a me 23 mahina, kēlā me kēia.
I kēia manawa, nui nā hoʻokolohua lapaʻau o nā ʻenehana anti-cancer hou ma Kina e ʻimi nei i nā maʻi. I ke kūkākūkā ʻana i nā lāʻau lapaʻau a me nā ʻenehana hou, hiki iā ʻoe ke hoʻokaʻaʻike aku i ka Beijing South Region Oncology Hospital International Department.
Helu Kelepona：4008803716
ʻIkepili WeChat: 17801183037
Email：myimmnet@163.com
Ka manawa hoʻouna: Aug-07-2025